This report presents a general method for screening cell surface receptors using so-called micromosaic immunoassays. This method employs a microfluidic chip having n (n = 11) independent flow paths to move cells over m (m = 11) lines of surface-patterned antibodies for screening individual cells in a parallel, combinatorial, fast and flexible manner. The antibodies are patterned as 30-µm-wide lines on a poly(dimethylsiloxane) layer used to seal the area of the chip in which screening is being monitored. Mouse hybridoma cells having CD44 cell surface receptors and anti-CD44 antibodies were used to establish a proof-of-concept for this method. Both the capture antibodies and the cells were fluorescently labelled to allow the position of the cells to be accurately tracked over the binding sites using an inverted fluorescence microscope. The chips and cells were maintained at a constant temperature between 20 to 37 • C, and flow velocities of the cells over the capture areas were 100-280 µm s −1 , resulting in a ∼0.1-0.3 s residency time of the cells on each of the eleven 30 × 30 µm s 2 capture areas. Binding of the cells appeared to be specific to the capture areas, with a yield of 30% when the assay was performed at a temperature of 37 • C and with a slow flow velocity. We suggest that this proof-of-concept is broadly applicable to the Electronic Supplementary Material Supplementary material is available in the online version of this article at http://dx.screening of cells for medical/diagnostic purposes as well as for basic research on the interaction of cells with surfaces.
Introduction
Cellular assays are used to study how chemicals, biomolecules and factors such as electrical and mechanical stimuli, radiation, and heat affect the viability, metabolism, differentiation, cytoskeleton, motility, adhesion, receptor trafficking, and apoptosis processes of cells (Rowan et al., 2002) . Cellular assays therefore are of fundamental importance in biology, medicine, pharmacology, and biotechnology. They are used both at a fundamental research level as well as for diagnostics. Whereas many assays focus on changes in the morphology, activity, or colour (due to staining) of cells, several assays aim at identifying cell membrane receptors to classify cells, detect diseases, or elucidate biological pathways (Mattanovich and Borth, 2006) . Cellular assays are also increasingly being used to test the safety of drugs and to identify potential drugs for cellular receptors. Cellular assays can require testing thousands of compounds at various concentrations, using individual compounds or a combination of compounds (Persidis, 1998) . Clearly, these assays can benefit from miniaturization by decreasing the size and cost of the infrastructure and equipment needed (Li et al., 2003; Prokop et al., 2004) . In addition, cells such as stem cells and cells from some mammalian cell lines are available in very limited quantities only.
Microfluidics are emerging as a powerful class of devices for performing miniaturized cellular assays (Wheeler et al., 2003; Pihl et al., 2005; Poulsen et al., 2005) , patterning cells (Khademhosseini et al., 2005; Chiu et al., 2000) , and controlling cellular environments (Takayama et al., 1999; Tourovskaia et al., 2005; Li Jeon et al., 2002) . These devices can accommodate microliter and sub-microliter volumes of samples and reagents, can provide faster time to results than conventional technologies, can effect multiple assays in parallel or serial assays with high throughput, and sometimes are portable. We have developed a class of microfluidics in which liquids move under the action of capillary forces (Delamarche et al., 1997 (Delamarche et al., , 1998 . These microfluidic chips are autonomous and do not need pumping elements. They can be used without peripherals for actuation. We call one independent flow path on such a microfluidic chip a capillary system (CS) (Juncker et al., 2002) . CSs can be cloned and arrayed so as to move a number of solutions independently and run assays in parallel. Key to using these chips is the accurate patterning of receptors for analytes on the surface of a poly(dimethylsiloxane) (PDMS) elastomer, which reversibly seals sections of the CSs.
Assays based on this approach can be two-dimensional and combinatorial. A first microfluidic chip with n CSs can be used to pattern n types of capture antibodies (Abs) on PDMS as parallel lines. A second chip having m CSs can be used to bring m samples over the surface-immobilized capture Abs. Ligand-receptor interactions between the capture Abs and their antigens from solution result in a maximum of n × m binding interactions, which can be displayed as a "micromosaic" of fluorescence signals if fluorescently-tagged detection Abs are used to reveal where antigens are captured on PDMS (Bernard et al., 2001) . Similar approaches for the combinatorial screening of clinical analytes (Rowe et al., 1999a,b; Kanda et al., 2004) , and single-stranded DNA analytes have been developed (Nelson et al., 2001) . A matrix of surface binding interactions can also be used to detect flowing antigens with a serial dilution strategy (Jiang et al., 2003) .
In this paper, we explore how the concept of micromosaic immunoassays (Bernard et al., 2001) can be applied to the screening of cells. Several reasons motivate this work. First, micromosaic immunoassays are efficient. One microliter of sample or less is sufficient to screen eight or more types of analyte. The short paths for diffusion of analytes in microchannels can greatly accelerate diffusion-limited steps. The flow of solutions in microfluidics is typically laminar and makes rinsing steps short and effective. A fluorescent sandwich immunoassay having ∼10 steps can be done in less than 10 min for detecting analytes at a concentration level of ∼1 mg mL −1 or in ∼45 min for analytes at concentrations down to 1 pM (Wolf et al., 2004; Cesaro-Tadic et al., 2004) . This method suggests that cells can be screened rapidly and using small volumes of sample. Second, using microfluidic chips the PDMS substrate for the assay can be patterned in a flexible manner prior to analyzing samples (Delamarche et al., 2005) . The accurate patterning of capture Abs on a PDMS surface limits the depletion of analytes from a small volume of sample and facilitates the reading of a large number (up to several hundreds) of fluorescent signals. The PDMS layer can be readily removed from the microfluidic chip at the end of the assay and the signals analyzed using a fluorescence scanner or microscope. With respect to cellular assays, it should then be possible to localize the interaction of cells with surface-bound receptors accurately. Third, the possibility to conduct assays and calibrate them simultaneously using reference samples may yield a better consistency and smaller intra-assay variation than assays do that are done as independent experiments. Similarly, it should be possible to screen different types of cells in parallel using a micromosaic format. In the remainder of this paper, we first review how a micromosaic immunoassay for screening cells can be set up and then provide a proof-of-concept by analyzing the trajectories of individual cells passing in microchannels over surface-immobilized antibodies.
Experimental

Chemicals and cells
Chemicals were purchased from Sigma-Aldrich or Fluka (Buchs, Switzerland) unless otherwise stated. Cells from the mouse hybridoma cell line PK136 were used for this work. Briefly, these cells secrete mouse IgG2a monoclonal antibody, which reacts with mouse natural killer cells. These hybridomas were obtained by fusion between SP2 myeloma cells and spleen cells (C3H × BALB/c) immunized with mouse spleen cells (Koo and Peppard, 1984; Kung et al., 2001) . The cells were cultured and prepared using phosphatebuffered saline with pH 7.4 (PBS), bovine serum albumin (BSA), Tween 20, fluorescein diacetate, dimethylsulfoxide (DMSO), Iscove's Modified Dulbecco's Medium (Gibco, Invitrogen, Switzerland), foetal calf serum, normal mouse serum, hyaluronidase, and propidium iodine. The cells were cultured with 5% atmospheric CO 2 at 37 • C in Iscove's Modified Dulbecco's Medium, which was supplemented with 10% foetal calf serum, in a cell incubator.
Anti-CD44 monoclonal antibodies (BD Biosciences, San Jose, CA), either conjugated with FITC or Phycoerythrin, were used as capture antibodies for the microfluidic-based assays (see below) as well as for fluorescence-activated cell sorting (FACS). FACS (FACScan, BD Biosciences, San Jose, CA) was used to verify the presence of CD44 on the PK136 cells before performing microfluidic-based assays as follows. First, cells were taken from the cell culture and washed, resuspended in PBS at a concentration of 2.5 × 10 6 cells mL −1 , and 200 µL of the suspension was loaded into the wells of a 96 microtiter plate (Falcon), which corresponds to ∼500,000 cells per well. The cell
